nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylbutazone—PTGS2—Triamcinolone—psoriasis	0.125	0.133	CbGbCtD
Phenylbutazone—PTGS2—Betamethasone—psoriasis	0.107	0.114	CbGbCtD
Phenylbutazone—SLC22A11—Methotrexate—psoriasis	0.0917	0.0977	CbGbCtD
Phenylbutazone—SLC22A6—Cyclosporine—psoriasis	0.0702	0.0748	CbGbCtD
Phenylbutazone—PTGS2—Dexamethasone—psoriasis	0.0624	0.0665	CbGbCtD
Phenylbutazone—CYP3A4—Calcitriol—psoriasis	0.0553	0.059	CbGbCtD
Phenylbutazone—SLC22A8—Methotrexate—psoriasis	0.0533	0.0568	CbGbCtD
Phenylbutazone—CYP2C9—Cholecalciferol—psoriasis	0.049	0.0522	CbGbCtD
Phenylbutazone—CYP3A4—Methoxsalen—psoriasis	0.043	0.0458	CbGbCtD
Phenylbutazone—SLC22A6—Methotrexate—psoriasis	0.0371	0.0396	CbGbCtD
Phenylbutazone—CYP2C9—Cyclosporine—psoriasis	0.0322	0.0343	CbGbCtD
Phenylbutazone—CYP3A4—Cholecalciferol—psoriasis	0.0285	0.0304	CbGbCtD
Phenylbutazone—CYP3A4—Mycophenolate mofetil—psoriasis	0.0247	0.0263	CbGbCtD
Phenylbutazone—CYP3A4—Triamcinolone—psoriasis	0.0247	0.0263	CbGbCtD
Phenylbutazone—CYP2C9—Dexamethasone—psoriasis	0.0212	0.0226	CbGbCtD
Phenylbutazone—CYP3A4—Betamethasone—psoriasis	0.0212	0.0226	CbGbCtD
Phenylbutazone—CYP3A4—Prednisolone—psoriasis	0.0209	0.0223	CbGbCtD
Phenylbutazone—CYP3A4—Hydrocortisone—psoriasis	0.0198	0.0211	CbGbCtD
Phenylbutazone—CYP3A4—Prednisone—psoriasis	0.0198	0.0211	CbGbCtD
Phenylbutazone—CYP3A4—Cyclosporine—psoriasis	0.0187	0.02	CbGbCtD
Phenylbutazone—CYP3A4—Dexamethasone—psoriasis	0.0123	0.0131	CbGbCtD
Phenylbutazone—PTGIS—endothelium—psoriasis	0.0107	0.322	CbGeAlD
Phenylbutazone—PTGS2—skeletal joint—psoriasis	0.0054	0.163	CbGeAlD
Phenylbutazone—PTGS2—synovial membrane of synovial joint—psoriasis	0.0041	0.124	CbGeAlD
Phenylbutazone—PTGIS—tendon—psoriasis	0.00347	0.105	CbGeAlD
Phenylbutazone—PTGS2—skin epidermis—psoriasis	0.00263	0.0795	CbGeAlD
Phenylbutazone—PTGS1—endothelium—psoriasis	0.002	0.0603	CbGeAlD
Phenylbutazone—PTGS2—endothelium—psoriasis	0.00191	0.0577	CbGeAlD
Phenylbutazone—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.00169	0.157	CbGdCrCtD
Phenylbutazone—PTGIS—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00162	0.0935	CbGpPWpGaD
Phenylbutazone—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.00136	0.126	CbGdCrCtD
Phenylbutazone—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.00132	0.122	CbGdCrCtD
Phenylbutazone—PTGIS—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00131	0.0758	CbGpPWpGaD
Phenylbutazone—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.00102	0.0949	CbGdCrCtD
Phenylbutazone—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00102	0.0587	CbGpPWpGaD
Phenylbutazone—PTGS1—skin of body—psoriasis	0.000853	0.0258	CbGeAlD
Phenylbutazone—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000818	0.076	CbGdCrCtD
Phenylbutazone—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000818	0.076	CbGdCrCtD
Phenylbutazone—PTGS2—skin of body—psoriasis	0.000816	0.0246	CbGeAlD
Phenylbutazone—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000795	0.0738	CbGdCrCtD
Phenylbutazone—PTGIS—Biological oxidations—CYP2S1—psoriasis	0.000697	0.0403	CbGpPWpGaD
Phenylbutazone—PTGS1—tendon—psoriasis	0.000649	0.0196	CbGeAlD
Phenylbutazone—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00063	0.0364	CbGpPWpGaD
Phenylbutazone—PTGS2—tendon—psoriasis	0.000621	0.0187	CbGeAlD
Phenylbutazone—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000618	0.0574	CbGdCrCtD
Phenylbutazone—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000618	0.0574	CbGdCrCtD
Phenylbutazone—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000604	0.0561	CbGdCrCtD
Phenylbutazone—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000415	0.024	CbGpPWpGaD
Phenylbutazone—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000403	0.0233	CbGpPWpGaD
Phenylbutazone—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000373	0.0346	CbGdCrCtD
Phenylbutazone—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000373	0.0346	CbGdCrCtD
Phenylbutazone—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000364	0.0338	CbGdCrCtD
Phenylbutazone—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000336	0.0195	CbGpPWpGaD
Phenylbutazone—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000298	0.0172	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—SOCS1—psoriasis	0.000276	0.0159	CbGpPWpGaD
Phenylbutazone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000261	0.0151	CbGpPWpGaD
Phenylbutazone—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000258	0.0149	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000257	0.0148	CbGpPWpGaD
Phenylbutazone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000247	0.0143	CbGpPWpGaD
Phenylbutazone—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000236	0.0137	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000214	0.0124	CbGpPWpGaD
Phenylbutazone—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000214	0.0124	CbGpPWpGaD
Phenylbutazone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000212	0.0123	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—LEP—psoriasis	0.000203	0.0118	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000195	0.0113	CbGpPWpGaD
Phenylbutazone—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000194	0.0112	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—PPARG—psoriasis	0.000177	0.0102	CbGpPWpGaD
Phenylbutazone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000172	0.00997	CbGpPWpGaD
Phenylbutazone—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00017	0.00984	CbGpPWpGaD
Phenylbutazone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000164	0.00948	CbGpPWpGaD
Phenylbutazone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000158	0.00912	CbGpPWpGaD
Phenylbutazone—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000154	0.00888	CbGpPWpGaD
Phenylbutazone—SLC22A11—SLC-mediated transmembrane transport—CP—psoriasis	0.000153	0.00884	CbGpPWpGaD
Phenylbutazone—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000143	0.00828	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—NDUFA5—psoriasis	0.00014	0.0081	CbGpPWpGaD
Phenylbutazone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00014	0.00808	CbGpPWpGaD
Phenylbutazone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000138	0.00797	CbGpPWpGaD
Phenylbutazone—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000135	0.00779	CbGpPWpGaD
Phenylbutazone—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000132	0.00764	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000131	0.00755	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000126	0.00729	CbGpPWpGaD
Phenylbutazone—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000125	0.00721	CbGpPWpGaD
Phenylbutazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00012	0.00694	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—CYP2S1—psoriasis	0.000119	0.00689	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.000118	0.00681	CbGpPWpGaD
Phenylbutazone—SLC22A8—SLC-mediated transmembrane transport—CP—psoriasis	0.000117	0.00674	CbGpPWpGaD
Phenylbutazone—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000113	0.00651	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000111	0.00642	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.00011	0.00636	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—STAT3—psoriasis	0.000109	0.00629	CbGpPWpGaD
Phenylbutazone—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000109	0.00629	CbGpPWpGaD
Phenylbutazone—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.000107	0.00618	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	0.000102	0.00589	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.93e-05	0.00574	CbGpPWpGaD
Phenylbutazone—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	9.73e-05	0.00563	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—TNF—psoriasis	9.41e-05	0.00544	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	9.29e-05	0.00537	CbGpPWpGaD
Phenylbutazone—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	8.76e-05	0.00507	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	8.73e-05	0.00505	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	8.73e-05	0.00505	CbGpPWpGaD
Phenylbutazone—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	8.63e-05	0.00499	CbGpPWpGaD
Phenylbutazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.37e-05	0.00484	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	8.02e-05	0.00464	CbGpPWpGaD
Phenylbutazone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.92e-05	0.00458	CbGpPWpGaD
Phenylbutazone—SLC22A11—Transmembrane transport of small molecules—CP—psoriasis	7.77e-05	0.00449	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	7.62e-05	0.00441	CbGpPWpGaD
Phenylbutazone—PTGIS—Adipogenesis—IL6—psoriasis	7.59e-05	0.00439	CbGpPWpGaD
Phenylbutazone—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.42e-05	0.00429	CbGpPWpGaD
Phenylbutazone—SLC22A11—Transmembrane transport of small molecules—CARM1—psoriasis	7.41e-05	0.00429	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.32e-05	0.00423	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	7.08e-05	0.0041	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	6.93e-05	0.00401	CbGpPWpGaD
Phenylbutazone—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.78e-05	0.00392	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	6.59e-05	0.00381	CbGpPWpGaD
Phenylbutazone—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.41e-05	0.0037	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	6.37e-05	0.00368	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—IL4—psoriasis	6.34e-05	0.00367	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.24e-05	0.00361	CbGpPWpGaD
Phenylbutazone—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	6.15e-05	0.00356	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	6.11e-05	0.00353	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transmembrane transport of small molecules—CP—psoriasis	5.93e-05	0.00343	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—CARM1—psoriasis	5.82e-05	0.00336	CbGpPWpGaD
Phenylbutazone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	5.78e-05	0.00334	CbGpPWpGaD
Phenylbutazone—SLC22A8—Transmembrane transport of small molecules—CARM1—psoriasis	5.65e-05	0.00327	CbGpPWpGaD
Phenylbutazone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.52e-05	0.00319	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.44e-05	0.00314	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—LEP—psoriasis	5.36e-05	0.0031	CbGpPWpGaD
Phenylbutazone—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	5.27e-05	0.00305	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	5.08e-05	0.00294	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	5.04e-05	0.00291	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—NOS2—psoriasis	5e-05	0.00289	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	4.95e-05	0.00286	CbGpPWpGaD
Phenylbutazone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	4.93e-05	0.00285	CbGpPWpGaD
Phenylbutazone—PTGS2—C-MYB transcription factor network—CD4—psoriasis	4.86e-05	0.00281	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	4.85e-05	0.0028	CbGpPWpGaD
Phenylbutazone—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	4.72e-05	0.00273	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—NDUFA5—psoriasis	4.31e-05	0.00249	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.05e-05	0.00234	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	4.03e-05	0.00233	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.02e-05	0.00232	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.95e-05	0.00229	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—IFNG—psoriasis	3.83e-05	0.00222	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—CYP2S1—psoriasis	3.66e-05	0.00212	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—CAT—psoriasis	3.58e-05	0.00207	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	3.56e-05	0.00206	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—HLA-A—psoriasis	3.56e-05	0.00206	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—NDUFA5—psoriasis	3.42e-05	0.00198	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.4e-05	0.00197	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—APOE—psoriasis	3.32e-05	0.00192	CbGpPWpGaD
Phenylbutazone—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	3.19e-05	0.00184	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.19e-05	0.00184	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	3.14e-05	0.00181	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—NOS2—psoriasis	3.09e-05	0.00179	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—CYP2S1—psoriasis	2.91e-05	0.00168	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—APOE—psoriasis	2.78e-05	0.00161	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—TYK2—psoriasis	2.53e-05	0.00147	CbGpPWpGaD
Phenylbutazone—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	2.53e-05	0.00146	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—TNF—psoriasis	2.48e-05	0.00143	CbGpPWpGaD
Phenylbutazone—PTGIS—Metabolism—PPARG—psoriasis	2.42e-05	0.0014	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—CD4—psoriasis	2.29e-05	0.00133	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—NDUFA5—psoriasis	2.26e-05	0.00131	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.25e-05	0.0013	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—TP53—psoriasis	2.19e-05	0.00126	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.17e-05	0.00125	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.11e-05	0.00122	CbGpPWpGaD
Phenylbutazone—PTGS2—Spinal Cord Injury—IL6—psoriasis	2e-05	0.00116	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.97e-05	0.00114	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—CYP2S1—psoriasis	1.93e-05	0.00111	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.92e-05	0.00111	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—CARM1—psoriasis	1.79e-05	0.00103	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—STAT3—psoriasis	1.77e-05	0.00103	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.69e-05	0.000976	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.67e-05	0.000967	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.52e-05	0.000881	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—NDUFA5—psoriasis	1.49e-05	0.000863	CbGpPWpGaD
Phenylbutazone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.49e-05	0.00086	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—CARM1—psoriasis	1.42e-05	0.000821	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.33e-05	0.000767	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—CYP2S1—psoriasis	1.27e-05	0.000734	CbGpPWpGaD
Phenylbutazone—PTGIS—Disease—IL6—psoriasis	1.24e-05	0.000717	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—CAT—psoriasis	1.1e-05	0.000636	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.01e-05	0.000583	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—CARM1—psoriasis	9.4e-06	0.000544	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.79e-06	0.000508	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—CAT—psoriasis	8.73e-06	0.000505	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—HLA-A—psoriasis	8.68e-06	0.000502	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—APOE—psoriasis	8.55e-06	0.000494	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—APOE—psoriasis	8.1e-06	0.000468	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—NOS2—psoriasis	7.55e-06	0.000437	CbGpPWpGaD
Phenylbutazone—PTGS1—Metabolism—PPARG—psoriasis	7.44e-06	0.00043	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—APOE—psoriasis	6.78e-06	0.000392	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—CARM1—psoriasis	6.2e-06	0.000359	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—TYK2—psoriasis	6.18e-06	0.000358	CbGpPWpGaD
Phenylbutazone—PTGS2—Metabolism—PPARG—psoriasis	5.91e-06	0.000342	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—CAT—psoriasis	5.78e-06	0.000334	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—CD4—psoriasis	5.59e-06	0.000323	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—APOE—psoriasis	4.49e-06	0.00026	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—STAT3—psoriasis	4.33e-06	0.00025	CbGpPWpGaD
Phenylbutazone—CYP2C9—Metabolism—PPARG—psoriasis	3.91e-06	0.000226	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—CAT—psoriasis	3.81e-06	0.000221	CbGpPWpGaD
Phenylbutazone—PTGS2—Disease—IL6—psoriasis	3.02e-06	0.000175	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—APOE—psoriasis	2.96e-06	0.000171	CbGpPWpGaD
Phenylbutazone—CYP3A4—Metabolism—PPARG—psoriasis	2.58e-06	0.000149	CbGpPWpGaD
